Prelude Capital Management’s ACELYRIN SLRN Stock Holding History

Prelude Capital Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36,220	Closed	-$89.5K	–	1319
2025 Q1	$89.5K	Sell	36,220 -51,961	-59%	-$124K	0.01%	1053
2024 Q4	$277K	Buy	88,181 +58,755	+200%	+$284K	0.02%	838
2024 Q3	$145K	Sell	29,426 -27,881	-49%	-$144K	0.01%	1114
2024 Q2	$253K	Buy	57,307 +16,300	+40%	+$76.4K	0.02%	873
2024 Q1	$277K	Buy	41,007 +30,501	+290%	+$232K	0.01%	935
2023 Q4	$78.4K	Buy	+10,506	New	+$89.7K	0.01%	1047

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's SLRN Position: Q2 2025 in Review

Prelude Capital Management sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 36,220 shares — an estimated $89.5K sold.

Prelude Capital Management first reported a position in SLRN in Q4 2023 and held it in 6 quarters. The position peaked at $277K in Q4 2024. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Prelude Capital Management reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 36,220 ACELYRIN shares in Q2 2025, an estimated $89.5K.
Prelude Capital Management first reported a position in ACELYRIN in Q4 2023 and held it in 6 quarters.
Prelude Capital Management's ACELYRIN position peaked at $277K in Q4 2024.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.